Equities Reward Long-Term Investors: Analyst Notes on Weatherford, ExxonMobil, Ally, UBIC Inc. and Fate Therapeutics

NEW YORK, December 22, 2014 /PRNewswire/ --

Moments ago, Analysts Review released new research updates concerning several important developing situations including Weatherford (NYSE: WFT), ExxonMobil (NYSE: XOM), Ally (NYSE: ALLY), UBIC Inc. (NASDAQ: UBIC), and Fate Therapeutics (NASDAQ: FATE). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

WFT Research Report: ( http://get.analystsreview.com/pdf/?c=Weatherford&d=22-Dec-2014&s=WFT ),

XOM Research Report: ( http://get.analystsreview.com/pdf/?c=ExxonMobil&d=22-Dec-2014&s=XOM ),

ALLY Research Report: ( http://get.analystsreview.com/pdf/?c=Ally%20Financial&d=22-Dec-2014&s=ALLY ),

UBIC Research Report: ( http://get.analystsreview.com/pdf/?c=UBIC%20Inc.&d=22-Dec-2014&s=UBIC ),

FATE Research Report: ( http://get.analystsreview.com/pdf/?c=Fate%20Therapeutics&d=22-Dec-2014&s=FATE ).

============

--

Analyst Update: Oil Discovery, Study Results, and Company Updates

Reviewed by: Rohit Tuli, CFA®  

The U.S. markets extended their gains for a third session on Friday with the S&P 500 adding up its second best week in almost two years. The Dow Jones Industrial Average finished at 17,804.80, up 0.15%, the NASDAQ Composite edged 0.36% higher at 4,765.38, and the S&P 500 advanced 0.46% to close the session at 2,070.65. The rally in the U.S. stocks was fueled by the Federal Reserve's assurance on Wednesday to take a patient approach towards raising interest rates, which calmed the investors over the policy outlook. On the other hand, the European markets ended Friday's session on a mixed note as Italian banking and healthcare stocks weighed down the wider benchmarks. The Asian markets extended the previous day's gain on Friday and ended on a positive note boosted by the momentum on Wall Street following the reassurance from Federal Reserve that interest rates would be hiked no sooner than mid-2015.

Shares of Weatherford International plc (Weatherford) continued their uptrend for the fourth straight session to end at $12.47 on December 19, 2014, as oil prices rebounded. Saudi Arabia - the world's largest oil exporter, expressed confidence that crude prices will rebound with global economic growth boosting demand. Read more about Weatherford, crude oil prices and the latest development affecting the Company.

Exxon Mobil Corporation (ExxonMobil) strikes more shale oil, gas in the Argentine region. Shares of Irving, Texas-based Company have rallied 8.4% in the last three trading sessions, as crude oil price recover from the lows. Read more about the gas find and energy outlook in our research report on ExxonMobil.

Ally Financial Inc. (Ally) finally exits Troubled Asset Relief Program (TARP) entered in December 2008, when the financial crisis was at the peak; Stock up 2.24%, amidst high trading volumes.  Read our research report on Ally to know more about the assistance under the TARP program, and the Company financials.

UBIC Inc.'s decision to terminate the agreement on acquisition of shares through third-party allocation of shares, acquisition of share warrants, and withdrawal of securities registration statement, sent the stock soaring by 21.40% at the close of the session. Read our research report on UBIC to know more about the latest developments affecting the Company and the stock performance in 2014, relative to the benchmark.

Fate Therapeutics Inc. announced its interim data from the ongoing Phase II PUMA study; Stock skyrocketed almost 42%. Fate Therapeutics, Inc. is a biopharmaceutical Company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases. Read our research report on Fate Therapeutics, to know about the drug, study results and management's viewpoint.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED